Levine Media Group

The Bio Report

Science EN ↓ Επεισόδια: 642

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Μην παραλείψεις να επισκεφτείς τη σελίδα του podcast και να στηρίξεις τον δημιουργό: thebioreport.podbean.com

Δημιουργός

Levine Media Group

Κατηγορία

Science

Ιστοσελίδα του podcast

thebioreport.podbean.com

Τελευταίο επεισόδιο

17 Νοε 2026

Πού να ακούσεις;

Podcast στην εφαρμογή Replaio Radio Έρχεται σύντομα

Τα podcast έρχονται σύντομα στην εφαρμογή. Εγκατάστησέ την τώρα και δες πρώτος μια εντελώς νέα προσέγγιση στα podcast

Κατέβασέ το από το Google Play Δωρεάν εγκατάσταση Android 10 εκ.+ λήψεις · βαθμολογία 4,7+ iOS σύντομα

Επεισόδια

A Scorecard to Improve Drugmakers’ Transparency 25.11.2015

A large number of clinical trials underlying the approval of drugs never come into public view. This not only has legal and ethical ramifications, but implications for the healthcare system as a whole. We spoke to Jennifer Miller, founding president of Bioethics International and assistant professor at the NYU School of Medicine about her recent study in BMJ Open, part of an effort to improve tran...

Forget the Chemistry Set, Mom, I Want a Bioreactor 19.11.2015

The power of genetic engineering will soon be available for the home thanks to the Amino One, a piece of hardware about the size of a laptop computer that would allow users to manipulate the DNA of microorganisms for productive purposes or just plain fun. We spoke to Julie Legault, founder and CEO of Amino One’s creator Amino Labs, about the device, its target market, and the implications of putti...

Ensuring Biological Tools Benefit the Environment 13.11.2015

New gene editing technologies are expanding the ease and power with which scientists can manipulate biological systems with the promising of addressing not only human health issues, but problems the plant faces with regards to food, fuel, and the environment. But while much of the concerns raised about the potential consequences of this technology have focused on its use in humans, Elizabeth Alter...

New SEC Rules Open Crowdfunding to the Masses 05.11.2015

The U.S. Securities and Exchange Commission last week finalized rules on crowdfunding that opens the door for the participation of non-accredited investors. The rules complete a long process for the commission set into motion by the passage of the JOBS Act. We spoke to Richard Swart, director of research for the Program for Innovation in Entrepreneurial and Social Finance at the University of Cali...

Harnessing Biology to Address Global Challenges 29.10.2015

Growing challenges in the areas of health, food, energy, and the environment have increased efforts to harness biology to create sustainable solutions to global problems. With advances in the ability to engineer microbes to perform desired tasks, the rapidly evolving area of synthetic biology is expected to fundamentally reshape industrial processes and give rise to a new bioeconomy. Leading scien...

Immunotherapies ETF Lets Biotech Investors Bet on Emerging Sector 22.10.2015

A new class of immunotherapies is promising to radically alter the treatment of cancers and has generated excitement among investors for their groundbreaking potential. Now the Loncar Cancer Immunotherapy ETF provides a way for investors to bet on the sector through an exchange traded fund that consists of both Big Pharma and emerging growth biotechs leading the sector. We spoke to Brad Loncar, CE...

Biotech Investors Turn Their Eyes to Policy Matters 16.10.2015

Wall Street doesn’t like uncertainty and there are a number of policy issues now brewing that threaten to create some uncertainty for the biotechnology industry. As the BIO Investor Forum kicks off in San Francisco October 20 and 21, bringing together investors and CEOs for two days of panels and presentations, the conference will turn its attention to policy issues and the effects they have on va...

Why the MedTech Industry Should Worry About Future Innovation 08.10.2015

The medtech industry has enjoyed robust M&A activity, strong financings, and a rise in R&D investments, but other numbers point to troubling developments that threaten the future health and growth of the industry, according to a new report from EY. We spoke to Ellen Licking, EY Life Sciences lead analyst, about the report, concerns about the venture capital industry’s move away from the sector, an...

Rare Disease Drug Developer Shows Speed of Business Model 01.10.2015

Vtesse, a rare disease drug development company, this week announced that it was initiating a late-stage pivotal trial for its lead experimental therapeutic to treat Niemann-Pick Type C1 disease. The start of the trial for the nine month old company represents a major milestone and suggest its history with the National Institutes of Health and the rare disease drug accelerator Cydan Development ma...

Ensuring Value-Based Care Addresses What Matters to Patients 24.09.2015

The U.S. Department of Health and Human Services has been working to move Medicare from fee-for-service to value-based payments. It’s seeking to get 90 percent of payments to being value-based by 2018. The problem, according to a recent Viewpoint in JAMA, is that when addressing life-ending chronic conditions faced by older patients, traditional professional standards that drive today’s metrics do...

California, Aid-in-Dying, and What We’ve Learned from Oregon 17.09.2015

The California legislature earlier this month passed a bill that would allow physicians to aid terminally ill patients who wanted to end their lives. California would become the fifth state to enact such legislation. We spoke to David Grube, national medical director of Compassion & Choices, a nonprofit working to expand end of life options, about the legislation, how attitudes among the public an...

FDA Guidance on Names for Biologics and Biosimilars and its Implications 10.09.2015

The U.S. Food and Drug Administration recently released long-awaited draft guidance regarding the naming of biologics, biosimilars, and interchangeable biologics. At the same time the agency released a proposed rule to apply the naming scheme to six current biological products with, or expected to soon have, biosimilar competitors. We spoke to Gillian Woollett, senior vice president with the healt...

Understanding the Cost and Value of Cancer Therapies 03.09.2015

The National Comprehensive Cancer Network in October will release a new tool designed to help doctors understand the value of different cancer therapies by taking into account the costs of treatments. The effort from the influential group follows similar initiatives by Sloan Kettering Cancer Center and the American Society of Clinical Oncology. We spoke to Bob Carlson, CEO of the National Comprehe...

Jimmy Carter’s Final Wish: Eradicating Guinea Worm 27.08.2015

President Jimmy Carter, at a recent press conference discussing his cancer diagnosis and treatment, expressed his wish to outlive the last Guinea worm. The Carter Center, since 1986, has led a global effort to eradicate Guinea worm disease with great success and its goal is within reach. We spoke to Ernesto Ruiz-Tiben, director of The Carter Center’s Guinea Worm Eradication Program, about its effo...

The Quest for a Pink Viagra 20.08.2015

Sprout Pharmaceuticals earlier this week won a controversial U.S. Food and Drug Administration approval of Addyi, the first drug approved in the United States to treat female sexual dysfunction. Following the news, Valeant Pharmaceuticals said it would acquire Sprout for $1 billion. We spoke filmmaker Liz Canner, director of the documentary Orgasm, Inc., about Addyi, the drug industry’s long stand...

Free Speech Ruling May Force FDA to Rethink Off-Label Marketing 14.08.2015

Earlier this month in a preemptive challenge from Amarin Pharma against the U.S. Food and Drug Administration a federal judge ruled that the FDA cannot prohibit a drugmaker from promoting the off-label use of a drug if it does so through the dissemination of truthful and non-misleading information. The decision about the First Amendment Rights of a pharmaceutical company is seen as a significant r...

Drugmakers Often Late to Report Serious Side Effects 06.08.2015

Drugmakers about 10 percent of the time fail to report serious adverse events to the U.S. Food and Drug Administration within the time required, according to a recent study in the Journal of the American Medical Association. We spoke to Pinar Karaca-Mandic, study co-author and associate professor of Health Policy and Management at the School of Public Health at the University of Minnesota, about t...

When Hospital Cause, Rather than Cure, Deadly Infections 30.07.2015

A growing problem with drug resistant infections acquired in hospitals is catching the eye of Consumer Reports, which has added the incidence of two common and deadly infections to their hospital ratings. The ratings come in the second part of a three-part investigation in the antibiotic crisis. We spoke to Doris Peter, director of Consumer Reports’ Health Ratings Center, about the study, what the...

Rethinking the Value and Price of Drugs 23.07.2015

The controversy over the high price of new drugs and the question of the value they provide will come under increased scrutiny thanks to a grant to a Boston-based nonprofit that works to get at these questions. The Laura and John Arnold Foundation this week announced it is providing $5.2 million to the Institute for Clinical and Economic Review aimed at transforming the way new drugs are evaluated...

Harnessing Stem Cells to Test Drug Safety 16.07.2015

Researchers at the University of California, Berkeley and the Gladstone Institutes have grown beating cardiac tissue from stem cells in work that may lead to new ways to quickly screen for drugs likely to cause birth defects in the heart and identify drugs that may be dangerous during pregnancy. We spoke to Bruce Conklin, a senior investigator at the Gladstone Institute of Cardiovascular Disease,...

CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries 09.07.2015

For many patients with rare and difficult to diagnose conditions, it can take many years and many doctors to find a correct answer. CrowdMed is trying to offering an alternative to patients by allowing them to tap the wisdom of crowds and letting medical detectives who sign on to the site try to find the right answer. We spoke to Jared Heyman, founder and CEO of CrowdMed, about the problem with th...

Biotech’s Record Performance and Looming Threats 02.07.2015

Last year, the biotechnology industry set records across the board for financial metrics, a reflection of product success, new drug approvals, and free-flowing investment capital. Despite the record performance, concerns continue about growing pricing pressure and maturing pipelines that represent challenges with which the industry must contend. We spoke to Glen Giovannetti, EY’s Global Life Scien...

What a Decade of Investment Tells Us about the Health of Biotech 25.06.2015

A detailed view of funding of emerging therapeutic companies over the past ten years shows despite a rebound in venture financing, companies continue to struggle to find early-stage money. Nevertheless, the report shows the overall health of investment in the sector is thriving. We spoke to Dave Thomas, senior director of industry research and analysis for the Biotechnology Industry Organization a...

What Activist Investors Can Teach Biotech Companies 18.06.2015

To improve the long-term value of biopharmaceutical companies, management should learn to think more like activist investors, according to a new report from EY. The report argues that capital allocation and strategic decision-making could benefit from company leaders setting aside their assumptions and challenging themselves by thinking more like outsiders. We spoke to Jeff Greene, Global Life Sci...

ALS Fight Carries Muller from Patient to Biotech CEO 11.06.2015

Bernard Muller was a successful businessman in the maritime and oil industry, but when he was diagnosed with the neurodegenerative disease ALS in 2010, he turned his entrepreneurial skills toward developing new therapies to treat the disease. Muller co-founded the world’s largest genetic research project for ALS, project MinE, and launched Treeway, a biotech company developing new therapies for AL...

Άκου το podcast The Bio Report στο Replaio

Ραδιόφωνο και podcast σε μία εφαρμογή - δωρεάν, χωρίς εγγραφή. Εγκατάστησέ την σήμερα και μη χάσεις την πρεμιέρα

Κατέβασέ το από το Google Play

Το Replaio δεν είναι εκδότης podcast - τα ονόματα των εκπομπών, τα εξώφυλλα και ο ήχος ανήκουν στους δημιουργούς τους και διανέμονται μέσω δημόσιων ροών RSS